Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Rezolute, Inc. filings on SEC EDGAR ↗
Rezolute announced the completion of patient enrollment in its Phase 3 upLIFT study of ersodetug for the treatment of tumor hyperinsulinism. The company expects to release topline data from the 16-participant registrational study in mid-December 2026.
Rezolute announced that the FDA recommended a pre-BLA meeting for ersodetug in congenital hyperinsulinism (HI) following a review of Phase 3 sunRIZE data. Although the trial missed its primary and key secondary endpoints, the Agency encouraged the meeting as a precursor to a potential Biologics License Application (BLA) submission. The company is also awaiting Phase 3 upLIFT results in tumor HI this quarter to finalize its overall regulatory strategy.
Counterparty
FDA
“We appreciate FDA’s thorough review of the extensive body of data generated in sunRIZE and are encouraged by the Agency’s recognition that this data will require in-depth evaluation during a formal BLA review.”
Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute